Anti-VEGF in Real-world

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

NCT02257632

Wet Age-Related Macular Degeneration

COMPLETED PHASE4

Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion

NCT04062370

Retinal Vein Occlusion Treatment Photocoagulation Burn to Retina +1 more

UNKNOWN PHASE4

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

NCT04296838

Uveitis Macular Edema Vascular Endothelial Growth Factor +1 more

TERMINATED PHASE2/PHASE3

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT02258009

Visual Impairment Due to Diabetic Macular Edema

WITHDRAWN PHASE4

Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema

NCT02329132

Diabetic Macular Edema

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-related Macular Edema Diabetic Macular Edema Choroidal Neovascular Membrane Non-proliferative Diabetic Retinopathy Retinal Vein Occlusion Proliferative Diabetic Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neovascular age-related macular edema

Patients with new-onset and recurrent Neovascular age-related macular edema.

Ranibizumab

Intervention Type DRUG

Ranibizumab 0.5mg/0.05ml intravitreal injection

Aflibercept

Intervention Type DRUG

Aflibercept 2.0mg/0.05ml intravitreal injection

Conbercept

Intervention Type DRUG

Conbercept 0.5mg/0.05ml intravitreal injection

Diabetic macula edema

Patients with new-onset and recurrent diabetic macula edema

Ranibizumab

Intervention Type DRUG

Ranibizumab 0.5mg/0.05ml intravitreal injection

Aflibercept

Intervention Type DRUG

Aflibercept 2.0mg/0.05ml intravitreal injection

Conbercept

Intervention Type DRUG

Conbercept 0.5mg/0.05ml intravitreal injection

Non-proliferative diabetic retinopathy/proliferative diabetic retinopathy

Patients with new-onset and recurrent non-proliferative diabetic retinopathy/proliferative diabetic retinopathy

Ranibizumab

Intervention Type DRUG

Ranibizumab 0.5mg/0.05ml intravitreal injection

Aflibercept

Intervention Type DRUG

Aflibercept 2.0mg/0.05ml intravitreal injection

Conbercept

Intervention Type DRUG

Conbercept 0.5mg/0.05ml intravitreal injection

Retinal vein occlusions

Patients with new-onset and recurrent retinal vein occlusions

Ranibizumab

Intervention Type DRUG

Ranibizumab 0.5mg/0.05ml intravitreal injection

Choroidal neovascularization

Patients with new-onset and recurrent choroidal neovascularization

Ranibizumab

Intervention Type DRUG

Ranibizumab 0.5mg/0.05ml intravitreal injection

Aflibercept

Intervention Type DRUG

Aflibercept 2.0mg/0.05ml intravitreal injection

Conbercept

Intervention Type DRUG

Conbercept 0.5mg/0.05ml intravitreal injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ranibizumab

Ranibizumab 0.5mg/0.05ml intravitreal injection

Intervention Type DRUG

Aflibercept

Aflibercept 2.0mg/0.05ml intravitreal injection

Intervention Type DRUG

Conbercept

Conbercept 0.5mg/0.05ml intravitreal injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases.
* Undergo intravitreal anti-VEGF therapy